Title: Rolapitant: first global approval.
Journal: Drugs 20151101
Title: Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Journal: Pharmacology, biochemistry, and behavior 20120701
Title: Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial.
Journal: Anesthesia and analgesia 20110401
Title: Management of postoperative nausea and vomiting: focus on palonosetron.
Journal: Therapeutics and clinical risk management 20090101
Title: The ATPase activity of cardiac myosin from failing and hypertropied hearts.
Journal: Journal of molecular and cellular cardiology 19751101
Title: Duffy RA, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokininNK1 receptor antagonist with centrally-mediated antiemetic effects inferrets. Pharmacol Biochem Behav. 2012 Jul;102(1):95-100.
Title: Rapoport B, et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015 Nov;23(11):3281-8.
